Skip to main content
OpenTrials
Recruiting

NCT Number: NCT01484236

National Lymphangioleiomyomatosis Registry, France

RE-LAM-CE is a registry of lymphangioleiomyomatosis cases in France. its aim is to determine the incidence and prevalence of lymphangioleiomyomatosis in France, including demographic information and information concerning the timing and modalities of diagnosis.

Based on the registry, we will set up a prospective cohort of patients. The database will include detailed medical information, particularly regarding progression of the respiratory function.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Lymphangioleiomyomatosis is a rare pulmonary disease occuring preferentially in women. Few data are available regarding the epidemiology of this disease, the frequency of the various forms with mild to moderate or severe disease, and the rapid or slow progression.

Several sources of information will be used in order to increase completeness. The registry will also allow to estimate the proportion of patients with lymphangioleiomyomatosis who are managed by the Reference Center and Competence Centers for rare lung diseases in France.

Data will be collected by a research assistant, and the study will be coordinated by the Pole IMER - Department of Public health and Epidemiology of HCL (Lyon Hospitals).

This study will provide a better knowledge on the natural course of the disease and the variability in severity and progression of lymphangioleiomyomatosis, and the applicability of diagnostic criteria proposed in 2009. This study will provide the first detailed epidemiological information on Lymphangioleiomyomatosis, will assess the management of this rare disease within the French National Plan for rare diseases 2005 - 2009, and will provide valuable medical information prior to the establishment of clinical trials

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with sporadic lymphangioleiomyomatosis or associated with Tuberous sclerosis.
  • patients diagnosed or hospitalized or seen in consultation since 01/01/2008

Exclusion criteria

  • None

Treatment and study plan

Primary outcomes

  1. Number of cases

    Time frame: 4 years

    Determine incidence and prevalence of lymphangioleiomyomatosis.

Secondary outcomes

  1. localisation of cases

    Time frame: 4 years

    Estimate the proportion of patients with lymphangioleiomyomatosis who are managed by the Reference Center and Centers of excellence for rare lung diseases in France (coverage rate of centers)

  2. Progression-free survival

    Time frame: 4 years

    Determine the frequency of the various forms with mild to moderate or severe, and rapid or slow evolution.

  3. Progression-free survival

    Time frame: 4 years

    Determine applicability of diagnostic criteria proposed in 2009

Study contacts

Contact information is provided by the study sponsor or research team.

Raphaële Guelminger, CRA

CONTACT

33-472-357-074

Vincent Cottin, MD

CONTACT

33-427-857-700

Sponsors and collaborators

Lead sponsor

Vincent COTTIN

Other

Collaborators

  • Hospices Civils de Lyon

Registry information

Acronym: RE-LAM-CE

Important dates

Study start
2012
Primary completion
2025
Study completion
2026
First posted
Dec 2, 2011
Registry last updated
Mar 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.